Egrifta (Tesamorelin) Nutrition for Best Outcomes
HealthRX.com
Diet was not tested with tesamorelin; glucose is the focus
Key numbers
- 150 mg/dLFasting glucose ceiling the pivotal trials required for enrollmentSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 50 mg/dLTriglyceride drop on tesamorelin in the larger trial (placebo rose 9 mg/dL)Source: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 15.2%Visceral fat loss on CT with tesamorelin in the larger trial (placebo rose 5.0%)Source: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
From the public record
Appetite, weight and nutrition terms in FDA adverse event reports for tesamorelin
Of 2,771 adverse event reports FDA had received for tesamorelin through 2026-10-28, 250 (9.0%) name at least one appetite, weight or nutrition term. The terms named most often are weight increased (146), weight decreased (53) and decreased appetite (28). Across every medicine in the database the same terms appear in 4.7% of reports.
| Measure | Value | Note |
|---|---|---|
| Reports naming at least one appetite, weight or nutrition term | 250 | |
| Share of all reports for tesamorelin | 9.0% | of 2,771 reports |
| Same terms across every medicine in FAERS | 4.7% | share of all reports in the database, for context |
| Weight increased | 146 reports | |
| Weight decreased | 53 reports | |
| Decreased appetite | 28 reports | |
| Dysgeusia | 15 reports | |
| Dehydration | 11 reports |
How this was calculated
Counted FAERS reports for this medicine that name any of 21 reaction terms about appetite, weight and nutrition, then each term on its own. A report can name several terms. Weight and appetite terms can describe the condition treated or the intended effect. Reports are unverified and do not show cause.
Reports for tesamorelin naming any of 21 MedDRA appetite, weight or nutrition terms
At a glance
- Approved use / excess abdominal fat in HIV-infected adults with lipodystrophy [1]
- Weight effect / weight-neutral; not indicated for weight loss [1]
- Current doses / Egrifta SV 1.4 mg, Egrifta WR 1.28 mg, subcutaneously once daily [1][3]
- Glucose signal / HbA1c of 6.5% or higher in 5% vs 1% on placebo by week 26 [1]
- Triglycerides / fell 50 mg/dL vs rose 9 mg/dL on placebo in the 412-patient trial [2]
- IGF-1 / 47% above 2 SDS and 36% above 3 SDS at 26 weeks [1]
Does what you eat change how tesamorelin works?
Tesamorelin binds growth hormone-releasing factor receptors on pituitary cells and triggers release of the body's own growth hormone, which the label describes as both anabolic and lipolytic [1]. Diet was not a study variable in the two pivotal trials behind approval: both compared a daily tesamorelin injection with placebo for 26 weeks in HIV-infected adults with excess abdominal fat [1]. It is not known whether a particular diet changes tesamorelin's effect on visceral fat.
The larger trial, published in 2007, enrolled 412 people. Visceral fat on CT fell 15.2% on tesamorelin and rose 5.0% on placebo; triglycerides fell 50 mg/dL against a 9 mg/dL rise, and the total-to-HDL cholesterol ratio fell 0.31 against a 0.21 rise [2].
The pivotal trials required fasting glucose below 150 mg/dL and excluded people with type 1 or type 2 diabetes [1].
Glucose: the label's main metabolic warning
The prescribing information flags glucose intolerance and diabetes as a labeled risk. HbA1c of 6.5% or higher developed in 5% of tesamorelin-treated patients versus 1% on placebo by week 26, a hazard ratio of about 3.3 (95% CI 1.4 to 9.6) [1]. The label says glucose should be evaluated before starting and monitored during treatment [1].
The label sets out no diet, carbohydrate target or sugar limit [1]. The World Health Organization's guideline recommends limiting free sugars for adults and children generally [4]; that is a population-level recommendation, not something tested with tesamorelin.
Triglycerides: what the trials measured
The 412-patient trial found triglycerides fell 50 mg/dL with tesamorelin and rose 9 mg/dL with placebo [2]. A pooled analysis of 806 patients from the two phase 3 trials found triglycerides fell 37 mg/dL versus a 6 mg/dL rise on placebo [5]. Neither analysis tested a diet.
Is weight loss the goal?
No. The label says Egrifta is not indicated for weight-loss management because its effect on weight is neutral [1]. Visceral fat was the trials' primary efficacy outcome [1][2]. Visceral fat loss was also not permanent: in the label's extension data, patients switched to placebo for weeks 26 to 52 after 26 weeks of tesamorelin saw visceral fat change by +16% to +22%, against about 0% to -5% in those who stayed on tesamorelin [1].
What about liver fat?
A separate 12-month trial measured liver fat in people with HIV and fatty liver; it tested tesamorelin versus placebo, not a diet. In that trial of 61 enrolled people, liver fat fell by an absolute 4.1 percentage points more on tesamorelin than on placebo (95% CI -7.6 to -0.7), and 35% versus 4% reached liver fat below 5% [6]. Glucose and HbA1c did not differ between groups [6]. Fatty liver is not an approved use, and effects on liver histology remain unproven [6].
Is there a rule about eating around the injection?
The two current products are dosed differently: Egrifta SV 1.4 mg and Egrifta WR 1.28 mg, each once daily into the abdomen with rotating sites [1][3]. The SV label says to give the dose immediately after reconstitution and throw away what is left [1]. The WR label says one reconstituted vial supplies 7 daily doses and is discarded 7 days after mixing [3]. The two products are not substitutable for each other [3].
The dosing summaries in the labels cover site, reconstitution and discard timing; they give no food-related instruction [1][3].
What people on Reddit report
Reddit posters in threads about tesamorelin dosing and timing. They disagree on whether eating before a dose matters, and none of them cite trial data that tested food.
Eating raises insulin and changes effectiveness of tesa. It might not make a difference, but I don't want to waste my money and potentially make the shots ineffective. So best practice is following the guideline of don't eat 2hr before or 30min afterRead the source discussion
All of the studies do not mention anything about fasting. You can take it with food, totally ok. If the researchers theorized or saw that timing made a difference, they would have had it under the methods and likely also had a control arm examining fasting vs non fasting.Read the source discussion
The 2 hours fasted part is mostly because food, especially carbs and large mixed meals, raises glucose and insulin. Tesa has a somewhat clashing relationship with insulin.Read the source discussion
Questions worth asking
Interactions the label lists
The label's interaction section addresses prescription drugs. People receiving glucocorticoid replacement for diagnosed hypoadrenalism may need higher maintenance or stress doses after starting tesamorelin, and the label says prednisone and cortisone acetate may be affected more than other steroids [1]. For drugs cleared by CYP450 enzymes, the label says to monitor for interactions; in healthy subjects, tesamorelin had no significant impact on simvastatin exposure [1].
Other label findings
Injection site reactions occurred in 25% of tesamorelin-treated patients versus 14% on placebo during the first 26 weeks [1]. Fluid retention can appear as peripheral edema (6% vs 2%), joint pain (13% vs 11%) and muscle pain (6% vs 2%) [1]. Hypersensitivity reactions occurred in 4% of patients and included itching, redness, flushing, hives and rash [1]. IGF-1 is monitored during therapy: at 26 weeks, 47% of patients were above 2 SDS and 36% above 3 SDS, and among those treated for 52 weeks, 34% and 23% [1].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Does diet change how well tesamorelin works?
Should I eat before or after my Egrifta injection?
Does tesamorelin raise blood sugar?
Is tesamorelin a weight-loss drug?
What does tesamorelin do to triglycerides?
What does the label say about drug interactions?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
How many mg of tesamorelin per week reddit?
Egrifta SV is dosed at 1.4 mg and Egrifta WR at 1.28 mg, each given once daily into the abdomen, not weekly. One reconstituted WR vial supplies 7 daily doses and is discarded 7 days after mixing.
Does tesamorelin make you shredded?
No. The label says Egrifta is not indicated for weight-loss management because its effect on weight is neutral. What it reduces is visceral fat, which fell 15.2% on tesamorelin versus a 5.0% rise on placebo in the 412-patient trial.
Can I eat after taking tesamorelin on Reddit?
The labels give no food-related instruction for the injection, and it is not known whether a particular diet changes tesamorelin's effect on visceral fat. The SV label says to give the dose immediately after reconstitution, and the WR label says a mixed vial is discarded 7 days after mixing.
References
Show all 8 referencesHide references
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70.
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Guideline: sugars intake for adults and children.
- Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304.
- Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830.
- Reddit participants. Tesamorelin: the peptide for visceral belly fat, what it does and how it's dosed (r/NTNPerformance). Accessed 2026-11-11.
- Reddit participants. Tesamorelin Dosing: 1mg vs 2mg, 5-on-2-off vs Daily, and Micro-Dosing — What the Data Actually Says (r/USPeptides). Accessed 2026-11-11.